ArticleStem cells translational medicine2025
Mesenchymal progenitor-derived proteoglycan 4 regulates the transdifferentiation of chondrocytes into osteoblasts during fracture healing.
Article in Stem cells translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lubricin Levels in Temporomandibular Joint Disorders: A Scoping Review.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
introductionProteoglycan 4 (PRG4), also known as lubricin, is essential for maintaining tissue homeostasis and acts as a lubricant that protects joint surfaces from wear and tear. Our previous studies have demonstrated that PRG4 plays multiple roles in wound healing in mice and pigs. Specifically, PRG4 derived from Hic1+ mesenchymal progenitor cells (MPCs) is crucial for maintaining tissue homeostasis in the dura mater near the spinal cord, and in the skin it contributes to ear wound healing in mice. Additionally, mice lacking PRG4 exhibit abnormal bone structure and function. However, the role of PRG4 in fracture healing remains unclear.
methodsTo investigate the role of PRG4 in fracture repair, we generated mice with a conditional deletion of Prg4 in the Hic1+ lineage. The presence and contribution of Hic1+ progenitors at the fracture site were assessed at 2‑ and 4‑weeks post‑injury (wpi). Bone healing quality was evaluated, and the cellular phenotype within the fracture callus was examined.
resultsWe observed Hic1+ progenitors at the fracture site at both 2‑ and 4‑wpi. Conditional deletion of Prg4 in these progenitors impaired the quality of new bone formation at the fracture site. Furthermore, PRG4 was required to maintain the cartilaginous phenotype of callus cells. In its absence, chondrocytes underwent premature transformation into osteoblasts, disrupting the normal progression of fracture healing. DISCUSSION: These findings provide new insights into the role of PRG4 in bone regeneration. PRG4, derived from Hic1+ MPCs, is critical for regulating the balance between chondrogenesis and osteogenesis during fracture repair. By preventing premature chondrocyte‑to‑osteoblast transition, PRG4 supports proper callus formation and bone healing. This work highlights the importance of PRG4 and Hic1+ MPCs in fracture repair and extends their known functions in tissue homeostasis and wound healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.